Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 220.00 GBp
Change Today -3.37 / -1.51%
Volume 5.2K
SLN On Other Exchanges
As of 11:35 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

silence therapeutics plc (SLN) Snapshot

222.25 GBp
Previous Close
223.38 GBp
Day High
222.25 GBp
Day Low
220.00 GBp
52 Week High
06/1/15 - 335.00 GBp
52 Week Low
10/16/14 - 168.00 GBp
Market Cap
Average Volume 10 Days
-0.18 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

silence therapeutics plc (SLN) Related Businessweek News

No Related Businessweek News Found

silence therapeutics plc (SLN) Details

Silence Therapeutics plc, a RNA technology company, engages in the development and delivery of RNA therapeutics. The company has an intellectual property portfolio, encompassing proprietary and in-licensed patents and patent applications, covering various aspects of its RNA based therapeutics. Its patented RNAi platform, AtuRNAi, is based on specific proprietary siRNA modules, stabilization technology, and other features. The company also has proprietary siRNA delivery technology platforms that comprise AtuPLEX, which delivers siRNA to the endothelial cells of the vascular system; and DACC delivery system that delivers siRNA to the vascular endothelial cells of the lung. Its lead clinical product, Atu027, completed a Phase IIa study in pancreatic cancer. The company is also planning for Phase Ib study of Atu027 for the treatment of head and neck cancer. Its pre-clinical programs include Atu111 for the treatment of lung diseases; products for immunotherapy; Messenger RNA (mRNA) delivery, a method of introducing messenger RNA activity into the cell, in conditions where this is of therapeutic interest; and MicroRNA delivery that mediate natural cellular mechanisms, which exist to regulate gene expression. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

58 Employees
Last Reported Date: 09/29/15
Founded in 1994

silence therapeutics plc (SLN) Top Compensated Officers

Chief Executive and Director
Total Annual Compensation: 200.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 167.0K GBP
Executive Director
Total Annual Compensation: 120.0K GBP
Compensation as of Fiscal Year 2014.

silence therapeutics plc (SLN) Key Developments

Silence Therapeutics plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

Silence Therapeutics plc reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company’s operating loss was GBP 4,199,000 against GBP 5,711,000 for the same period in the last year. Loss for the period before taxation was GBP 4,141,000 against GBP 5,624,000 for the same period in the last year. Loss per basic and diluted ordinary equity share was 7.1 pence against 11.5 pence for the same period in the last year. Loss after taxation was GBP 4,141,000 against GBP 5,624,000 for the same period in the last year. Net cash outflow from operating activities was GBP 4,801,000 against GBP 5,232,000 for the same period in the last year. Additions to property, plant and equipment were GBP 114,000 against GBP 59,000 a year ago. Additions to intangible assets were GBP 2,000 against GBP 1,000 for the same period in the last year.

Silence Therapeutics Mulls Acquisitions

Silence Therapeutics plc (AIM:SLN) is seeking acquisitions. New investors brought in through share issuance in April, 2015 will support in expanding R&D activities and enable Silence Therapeutics to capitalize on strategic in-licensing and acquisition opportunities.

Silence Therapeutics plc Announces Management Changes

Silence Therapeutics plc announced that chief executive officer, Ali Mortazavi, has resumed his full time duties as he returns from compassionate leave. Following his return, Dr. Alastair Riddell, who acted as executive chairman during Ali's leave of absence has retired from the board of directors to concentrate on his other business interests. Dr. Riddell has been succeeded by Dr. Stephen Parker, who has assumed the role of non-executive chairman, effective immediately, having served the company as a non-executive director since November 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLN:LN 220.00 GBp -3.37

SLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arbutus Biopharma Corp $6.12 USD -0.14
Benitec Biopharma Ltd A$0.48 AUD -0.01
Dicerna Pharmaceuticals Inc $10.05 USD +0.88
Galena Biopharma Inc $1.74 USD +0.01
Regulus Therapeutics Inc $6.86 USD +0.29
View Industry Companies

Industry Analysis


Industry Average

Valuation SLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15,816.6x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18,916.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SILENCE THERAPEUTICS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at